1-4 of 4
Alvaro Taus
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Free
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Valentina Boni, Alvaro Taus, Joan Albanell, Marie-Paule Sablin, Marie Alt, Ratislav Bahleda, Andrea Varga, Christophe Boetsch, Izolda Franjkovic, Florian Heil, Angelika Lahr, Katharina Lechner, Anthony Morel, Tapan Nayak, Simona Rossomanno, Kevin Smart, Kay Stubenrauch, Oliver Krieter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1536–1545.
https://doi.org/10.1158/1078-0432.CCR-17-1588
Published: 02 April 2018
View article titled, First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Free
Didier Meulendijks, Wolfgang Jacob, Emile E. Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Alvaro Taus, Tania Fleitas, Andres Cervantes, Martijn P. Lolkema, Marlies H.G. Langenberg, Maja J. De Jonge, Stefan Sleijfer, Ji-Youn Han, Antonio Calles, Enriqueta Felip, Sang-We Kim, Jan H.M. Schellens, Sabine Wilson, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Suzana Vega-Harring, Rajiv Dua, Maitram Nguyen, Lori Steiner, Celine Adessi, Francesca Michielin, Birgit Bossenmaier, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5406–5415.
https://doi.org/10.1158/1078-0432.CCR-17-0812
Published: 14 September 2017
View article titled, Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Open the PDF for Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Free
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, Alvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas Kanonnikoff, Andres Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau Soerensen, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Celine Adessi, Francesca Michielin, Keelara Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 877–885.
https://doi.org/10.1158/1078-0432.CCR-15-1683
Published: 14 February 2016
View article titled, First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Open the PDF for First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

Free
Israel Cañadas, Federico Rojo, Álvaro Taus, Oriol Arpí, Montserrat Arumí-Uría, Lara Pijuan, Silvia Menéndez, Sandra Zazo, Manuel Dómine, Marta Salido, Sergi Mojal, Antonio García de Herreros, Ana Rovira, Joan Albanell, Edurne Arriola
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (4): 938–950.
https://doi.org/10.1158/1078-0432.CCR-13-1330
Published: 16 February 2014
View article titled, Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
Open the PDF for Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer in another window
Includes: Supplementary data